Insmed reported $178.55M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
DBV Technologies USD 15.97M 279K Sep/2025
Gilead Sciences USD 4.74B 172M Mar/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 178.55M 37.7M Mar/2026
Novartis USD 12.29B 3.3B Dec/2025
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026